Merck Sharp + Dohme Corp.

Neuromed Pharmaceuticals Ltd.

Feng Ye

Pengcheng Patrick Shao

Petr Vachal

Yongxin Han

Alexander Pasternak

Xianhai Huang

Li Xiao

Dane James Clausen

Hongjun Zhang

Ping Chen

Xavier Fradera

Joseph A Kozlowski

Paul E Finke

Frank W Bennett

Shuwen He

Liangqin Guo

Deyou Sha

Revathi Reddy Katipally

Jian Liu

Wanying Sun

Qinglin Pu

Joseph Leslie Duffy

Sriram Tyagarajan

Debra L Ondeyka

Yi Zang

Prasun K Chakravarty

Wensheng Yu

Dong Xiao

Jianming Bao

F Anthony Romero

Feroze Ujjainwalla

Zhicai Wu

Rui Liang

Yusheng Xiong

Guoqing Li

Harold B Wood

Derun Li

Lin Chu

Hassan Pajouhesh

James Francis Dropinski

Tanweer A Khan

Weiguo Liu

Yanbing Ding

John J Acton, Iii

Angela Dawn Kerekes

Guizhen Dong

Fengqi Zhang

Vincent Colandrea

Edward C Sherer

Hyewon Youm

Rui Zhang

Claire Lankin

Alexander J Kim

Yang Yu

Remond Moningka

Zahid Hussain

Jason Eugene Imbriglio

Andreas Verras

Qingmei Hong

Theodore A Martinot

Michael A Plotkin

Jayanth Thiruvellore Thatai

Aaron Zwicker

Patrick Shao

Venukrishnan Komanduri

Anthappan Tony Kurissery

Vincent J Colandrea

Jayanth Thiruvellore Thatal

Joseph L Duffy

John J Iii Acton

Zahid Hussian

Anthony Romero

The present invention relates to Compounds of Formula I: and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treatment of cardiometabolic diseases including high blood pressure, heart failure, kidney disease, and diabetes in a subject.

Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

[1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors

Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, wherein D1, D2 and D3 are each N, CH, or substituted CH, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. 

Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, wherein X is (CH) or O, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: 

Fused bicyclic isoxazolines as inhibitors of cholesterol ester transfer protein

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol and reducing LDL-cholesterol in human patients and for treating or preventing atherosclerosis. 

Cyclic amine substituted heterocyclic CETP inhibitors

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. 

Fused bicyclic oxazolidinone CETP inhibitor

Substituted spirocyclic amines of structural formula (I) are selective antagonists of the somatostatin subtype receptor 5 (SSTR5) and are useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as Type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, Metabolic Syndrome, depression, and anxiety. 

Spiroxazolidinone compounds

A series of substituted aryl sulfone derivatives represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, calcium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, urinary incontinence, itchiness, allergic dermatitis, epilepsy, diabetic neuropathy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, sleep disorder, bipolar disorder and stroke, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.

Substituted aryl sulfone derivatives as calcium channel blockers

Growing community of inventors

Scotch Plains, NJ, United States of America

Feng Ye